Navigation Links
TenX Biopharma Licenses Zanolimumab From Genmab
Date:2/4/2010

PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN).

Under the terms of the agreement, Genmab will receive an up-front license fee of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab.  TenX will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.  

"Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate," said Gardiner F.H. Smith, Chief Executive Officer of TenX Biopharma. "We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency."

Asher Nathan, Managing Partner of Zoticon Bioventures and the lead investor in TenX, said "TenX and zanolimumab represent the fourth late stage drug funding which we've led in the past two years.  I'm delighted that this important product will be available in the future, and look forward to the management team at TenX continuing to build value with novel cancer therapeutics."

"Genmab is pleased to find a partner who wishes to take zanolimumab forward in development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer.  "This is good news for patients who may one day benefit from treatment with zanolimumab."

About TenX

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.  For more information visit www.tenxbiopharma.com.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.  For more information visit www.genmab.com.

This press release contains forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. TenX does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Contact:  Gardiner F.H. Smith, Chief Executive Officer, TenX Biopharma

T: (304) 982-1240; E: gsmith@tenxbiopharma.com

SOURCE TenX Biopharma, Inc.

RELATED LINKS
http://www.tenxbiopharma.com

'/>"/>

SOURCE TenX Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
Breaking Medicine Technology:
(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, ... the most comprehensive mental health systems reform legislation in more than fifty years. ... and the commitment of our elected officials to improving mental health services and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... their bodies, a researcher at the Icahn School of Medicine at Mount Sinai ... study found that when young children are exposed to secondhand marijuana smoke, measurable ...
(Date:12/7/2016)... CITY, UTAH (PRWEB) , ... December 07, 2016 ... ... today announced the release of Smart Device Remote Control through a new partnership ... across all platforms and strengthens its mobile solutions to help businesses maximize their ...
(Date:12/7/2016)... Georgia (PRWEB) , ... December ... ... today it has acquired Presence Technology, S.L. (“Presence”) for a purchase price ... price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. ...
Breaking Medicine News(10 mins):